On March 29, 2010, Judge Mitchell S. Goldberg upheld antitrust lawsuits filed by the Federal Trade Commission (FTC) and private plaintiffs against drug maker Cephalon, Inc. (Cephalon), alleging that Cephalon conspired with four generic drug manufacturers to delay generic competition for the wakefulness drug Provigil. [1] Despite refusing to dismiss the cases, Judge Goldberg adopted the “scope of the patent” test to evaluate the sufficiency of the complaints, keeping in line with the consensus among federal courts that have evaluated the legality of Hatch-Waxman patent litigation settlements. [2] Judge Goldberg’s unwillingness to dismiss the complaints stemmed from the plaintiffs’
Share on
|
|
The US District Court for the Eastern District of Pennsylvania adopts the "scope of patent" test for analyzing Hatch-Waxman patent settlements (Cephalon)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
